This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
Health Insurance Industry Outlook - May 2018
by Zacks Equity Research
Higher medical enrollment, surging revenues, medical cost management and an increasing share of revenues from complementary services helped results.
Fred's Confirms Sale of Specialty Pharmacy Unit, Stock Up
by Zacks Equity Research
Fred's (FRED) implements its long-standing plans to divest specialty pharmacy segment to CVS Health Corporation.
Fred's (FRED) Q4 Loss Widens Year Over Year, Stock Loses 6%
by Zacks Equity Research
Fred's (FRED) continues to struggle with its front store business. However, the company remains focused on turnaround.
CVS Health (CVS) Beats on Q1 Earnings, Revenues Lag Estimate
by Zacks Equity Research
CVS Health (CVS) witnessed year-over-year growth in Pharmacy Services Segment on the back of growth in pharmacy network and specialty pharmacy volume as well as brand inflation.
Fred's Stock Jumps Over 13% in a Day, 2 Things You Must Note
by Zacks Equity Research
Fred's (FRED) has rescheduled its earnings announcement date.This is solely connected to Fred's plans to divest its specialty pharmacy business.
Why Are Walgreens and CVS Shares Surging Today?
by Ryan McQueeney
Shares of several major pharmaceutical retailers--including Walgreens (WBA) and CVS Health (CVS)--surged in afternoon trading Monday after reports emerged that e-commerce behemoth Amazon (AMZN) has shelved its plan to sell prescription drugs to doctors and hospitals.
Factors Setting the Stage for Fred's (FRED) in Q4 Earnings
by Zacks Equity Research
Fred's (FRED) has been reeling under soft comparable store sales for quite some time now. Let's see if Fred???s strategic initiatives can provide any respite in Q4.
Can Strategic Efforts Aid Fred's to Achieve a Turnaround?
by Zacks Equity Research
Fred's (FRED) focuses on pharmacy organization and expense reduction to achieve turnaround. However, receding comps continue to hurt.
Cigna to Take Over Express Scripts (ESRX) for $67 Billion
by Zacks Equity Research
Per a definitive agreement, Cigna will take over Express Scripts (ESRX) in a cash-and-stock transaction worth $67 billion.
Why Is CVS Health Corporation (CVS) Down -9.2% Since its Last Earnings Report?
by Zacks Equity Research
CVS reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.